| Symbol | BEAM |
|---|---|
| Name | BEAM THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 238 MAIN STREET, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 857 - 327-8775 |
| Fax | — |
| — | |
| Website | https://www.beamtx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001745999 |
| Description | Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The companys portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. Additional info from NASDAQ: |
Evans John M. 🟡 adjusted position in 50.0K shares (3 derivative) of Beam Therapeutics Inc. (BEAM) at $35.91 ($1.8M) Transaction Date: Jun 29, 2026 | Filing ID: 292526
Read more📋 JOHN M EVANS (Officer) plans to sell 25K shares of BEAM THERAPEUTICS INC. (at $35.49 each, total $887K) Filed: Jun 29, 2026 | ID: 006578
Read moreFMR LLC 🔴 sold 284.9K shares of Beam Therapeutics Inc. (BEAM) at $35.26 ($10.0M) Transaction Date: Jun 25, 2026 | Filing ID: 288078
Read moreCiaramella Giuseppe 🟡 adjusted position in 0 shares (2 derivative) of Beam Therapeutics Inc. (BEAM) at $1.03 Transaction Date: Jun 17, 2026 | Filing ID: 277509
Read moreShaw Christi 🟢 acquired 19.7K shares (1 derivative) of Beam Therapeutics Inc. (BEAM) at $29.55 Transaction Date: Jun 03, 2026 | Filing ID: 259529
Read moreWalsh Kathleen E 🟢 acquired 19.7K shares (1 derivative) of Beam Therapeutics Inc. (BEAM) at $29.55 Transaction Date: Jun 03, 2026 | Filing ID: 259526
Read moreMARAGANORE JOHN 🟢 acquired 19.7K shares (1 derivative) of Beam Therapeutics Inc. (BEAM) at $29.55 Transaction Date: Jun 03, 2026 | Filing ID: 259524
Read moreFishman Mark 🟢 acquired 19.7K shares (1 derivative) of Beam Therapeutics Inc. (BEAM) at $29.55 Transaction Date: Jun 03, 2026 | Filing ID: 259536
Read moreGuindo Chirfi 🟢 acquired 19.7K shares (1 derivative) of Beam Therapeutics Inc. (BEAM) at $29.55 Transaction Date: Jun 03, 2026 | Filing ID: 259534
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07373639 | A Long-term Follow-up Study in Patients Who Received BEAM-101 | — | Hemoglobinopathy | Recruiting | 2025-12-15 | 2043-02-12 | ClinicalTrials.gov |
| NCT07304791 | This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess… | Phase1 | Healthy Subjects | Recruiting | 2025-10-27 | 2026-05-29 | ClinicalTrials.gov |
| NCT06934382 | Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia… | Phase1 | T-Cell Acute Lymphoblastic Leukemia/Lymphoma | Recruiting | 2025-04-29 | 2031-05-30 | ClinicalTrials.gov |
| NCT06735755 | A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM… | Phase1 | Glycogen Storage Disease Type Ia | Recruiting | 2024-12-06 | 2027-12-30 | ClinicalTrials.gov |
| NCT07183735 | A Crossover Trial to Examine the Efficacy of a Powder to Improve Sleep Quality … | Na | Sleep | Completed | 2024-07-02 | 2024-10-17 | ClinicalTrials.gov |
| NCT06389877 | A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With … | Phase1 | Alpha 1-Antitrypsin Deficiency | Recruiting | 2024-06-19 | 2030-05-01 | ClinicalTrials.gov |
| NCT05885464 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T… | Phase1 | Lymphoblastic Lymphoma | Active_Not_Recruiting | 2023-05-25 | 2026-12-01 | ClinicalTrials.gov |
| NCT06071377 | Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT) | — | Sickle Cell Trait | Recruiting | 2023-04-01 | 2027-02-01 | ClinicalTrials.gov |
| NCT05456880 | BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With… | Phase1 | Sickle Cell Disease | Active_Not_Recruiting | 2022-08-30 | 2028-02-01 | ClinicalTrials.gov |
| NCT05521243 | An Exploratory Investigation of a Supplement to Enhance Sleep Quality and Quant… | Na | Sleep | Completed | 2022-05-09 | 2022-09-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Allogeneic anti-CD7 CAR-T cells (BEAM-201) | Other | Phase PHASE1 | T-Cell Acute Lymphoblastic Leukemia/Lymphoma | RECRUITING | NCT06934382 |
| Placebo Comparator | Other | Phase PHASE1 | Healthy Subjects | RECRUITING | NCT07304791 |
| BEAM-103 | Other | Phase PHASE1 | Healthy Subjects | RECRUITING | NCT07304791 |
| Placebo | Other | Approved | Sleep | COMPLETED | NCT05521243 |
| Beam Organics Dream Powder Extra Strength | Other | Approved | Sleep | COMPLETED | NCT05521243 |
| Beam Organics Dream Powder | Other | Approved | Sleep | COMPLETED | NCT05521243 |
| BEAM-201 | Other | Phase PHASE1 | Lymphoblastic Lymphoma | ACTIVE_NOT_RECRUITING | NCT05885464 |
| Placebo Control | Other | Approved | Sleep | COMPLETED | NCT07183735 |
| BEAM Dream Powder | Other | Approved | Sleep | COMPLETED | NCT07183735 |
| Biologic Specimen Collection | Other | Preclinical | Sickle Cell Trait | RECRUITING | NCT06071377 |
| BEAM-301: Single dose of BEAM-301 administered by IV | Other | Phase PHASE1 | Glycogen Storage Disease Type Ia | RECRUITING | NCT06735755 |
| BEAM-101 | Other | Phase PHASE1 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT05456880 |
| Allogeneic anti-CD7 CAR-T cells (BEAM-201) | Other | Phase PHASE1 | T-Cell Acute Lymphoblastic Leukemia/Lymphoma | RECRUITING | NCT06934382 |
| Long-Term Follow-up Study of patients who received BEAM-101 | Other | Preclinical | Hemoglobinopathy | RECRUITING | NCT07373639 |
| BEAM-302 | Other | Phase PHASE1 | Alpha 1-Antitrypsin Deficiency | RECRUITING | NCT06389877 |
| Long-Term Follow-up Study of patients who received BEAM-101 | DRUG | Preclinical | Hemoglobinopathy | RECRUITING | NCT07373639 |
| Placebo Comparator | DRUG | Phase PHASE1 | Healthy Subjects | RECRUITING | NCT07304791 |
| BEAM-103 | DRUG | Phase PHASE1 | Healthy Subjects | RECRUITING | NCT07304791 |
| Allogeneic anti-CD7 CAR-T cells (BEAM-201) | BIOLOGICAL | Phase PHASE1 | T-Cell Acute Lymphoblastic Leukemia/Lymphoma | RECRUITING | NCT06934382 |
| BEAM-301: Single dose of BEAM-301 administered by IV | DRUG | Phase PHASE1 | Glycogen Storage Disease Type Ia | RECRUITING | NCT06735755 |
| BEAM-302 | DRUG | Phase PHASE1 | Alpha 1-Antitrypsin Deficiency | RECRUITING | NCT06389877 |
| Biologic Specimen Collection | OTHER | Preclinical | Sickle Cell Trait | RECRUITING | NCT06071377 |
| BEAM-201 | BIOLOGICAL | Phase PHASE1 | Lymphoblastic Lymphoma | ACTIVE_NOT_RECRUITING | NCT05885464 |
| BEAM-101 | BIOLOGICAL | Phase PHASE1 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT05456880 |